DOCSLIB.ORG

INTERNATIONAL NARCOTICS RESEARCH CONFERENCE 11–14 JULY 2016 Bath Assembly Rooms Bath, United Kingdom

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
INTERNATIONAL NARCOTICS RESEARCH CONFERENCE 11–14 JULY 2016 Bath Assembly Rooms Bath, United Kingdom TODAY’S SCIENCE TOMORROW’S MEDICINES INTERNATIONAL NARCOTICS RESEARCH CONFERENCE 11–14 JULY 2016 Bath Assembly Rooms Bath, United Kingdom Programme Programme v2_mono.indd 1 01/07/2016 16:23 EXECUTIVE COMMITTEE CONFERENCE ORGANISING COMMITTEE Fred Nyberg (Sweden, President) Chris Bailey (UK) John Traynor (USA, Past-President) Eamonn Kelly (UK) Lawrence Toll (USA, Treasurer) Graeme Henderson (UK) Craig W. Stevens (USA, Information Officer) Elena Bagley (Australia) Jose Moron-Concepcion (USA) Alexis Bailey (UK) Cathy Cahill (USA) Alistair Corbett (UK) Amynah Pradhan (USA) Steve Husbands (UK) Dominique Massotte (France) Susie Ingram (USA) Christoph Stein (Germany) Dominique Massotte (France) Chris Bailey (UK) Jose Moron-Concepcion (USA) Chagi Pick (Israel) Fred Nyberg (Sweden) Paul Bigliardi (Singapore) Amynah Pradhan (USA) Kazutaka Ikeda (Japan) Christoph Stein (Germany) Contents INFORMATION FOR PARTICIPANTS 3 EXHIBITOR & SPONSOR INFORMATION 5 LOCATION MAP 8 INRC 2016 AWARDEES 9 MEETING PROGRAMME 10 ABSTRACTS 19 Follow @BritPharmSoc and @INRC2016 on Twitter Use the hashtag #INRCBath to share your thoughts and see what others are saying For more information at attending or presenting at other Society meetings find us at the registration desk, email [email protected] or visit www.bps.ac.uk 2 3 Programme v2_mono.indd 2 01/07/2016 16:23 Information for participants KEY TIMINGS Sunday 10 July 15.00–17.00 Registration (Bath Assembly Rooms) 20.00–21.30 Welcome reception (Pump Rooms) Monday 11 July 08.00 Registration 08.30 Plenary Lecture 09.30 Opioid receptor structure and function 10.35 Coffee 10.55 Opioid receptor structure and function 12.30 Lunch 13.30 New Roles for opioids 14.35 Coffee 14.55 New Roles for opioids 16.30 Datablitz Session 17.00 Poster Session A 19.00 Close Pub of the night – Bath Brew House Tuesday 12 July 08.00 Registration 08.15 Plenary Lecture 09.15 Opioids, craving and addiction 10.20 Coffee 10.40 Opioids, craving and addiction 12.15 Lunch 13.15 Opioids: from itch to cancer 14.20 Coffee 14.40 Opioids: from itch to cancer 16.15 Datablitz Session 16.45 Poster Session B 18.45 Close Pub of the night – The Bell Wednesday 13 July 08.00 Registration 08.15 Founders' Lecture 09.15 Opioid receptor regulation and crosstalk 10.45 Coffee 11.05 Opioid receptor regulation and crosstalk 12.40 Lunch 13.40 Free time or grant-writing and careers workshop Thursday 14 July 08.15 Plenary Lecture 09.15 Neuronal plasticity: pain and addiction 10.20 Coffee 10.40 Neuronal plasticity: pain and addiction 12.15 Lunch 13.15 Young Investigator Symposium: Pain and perception 14.40 Coffee 15.00 Young Investigator Symposium: Pain and perception 16.15 INRC Business Meeting 16.40 Conference Close 19.00 Conference Dinner 2 3 Programme v2_mono.indd 3 01/07/2016 16:23 POSTER PRESENTERS PHOTOGRAPHIC POLICY Posters should be A0 portrait format. Posters for Monday’s Please note that photographs taken at this meeting may poster session should be put up first thing on Monday be used on our website, social networking sites, and in morning and taken down after the poster session that other publications. If you do not wish to have your image evening. Posters for Tuesday’s poster session should be used for this purpose, please speak to a BPS staff member put up first thing on Tuesday morning and taken down or email [email protected]. after the poster session that evening. Please check the programme for the timings of the poster sessions. Authors TOURIST INFORMATION with odd poster numbers will present for the first hour of Bath Tourist Office each poster session and authors with even numbers will Abbey Churchyard present for the second hour of each poster session. Velcro Bath fastenings will be provided. Posters not taken down after BA1 1LY the poster sessions will need to be removed from the boards, and if not collected, will be disposed of. ORAL COMMUNICATION PRESENTERS Please bring your presentation on a USB stick and load it on the laptop in the lecture theatre in the refreshment/ lunch break that takes place before your session starts. If you are a Mac user, you will need to provide your own laptop and cabling/adaptors. CERTIFICATES OF ATTENDANCE/ CPD CERTIFICATES If you require a certificate of attendance or a CPD certificate, please ask at the registration desk. Please note that if you do not sign for these at the meeting, we will be unable to issue them. INTERNET ACCESS Complimentary Wi-Fi access will be available throughout the meeting at the venue. Network name: Assembly Rooms Guest. Simply click ‘Join’ (no password required). REFRESHMENTS Scheduled tea and coffee breaks will take place during both days of the conference and will be held in the breakout areas. Lunch is also included on both days and will be served in the breakout areas. SOCIAL PROGRAMME The Welcome Reception will take place at the Pump Rooms from 8pm to 9.30pm on Sunday 10 July. The address for the Pump Rooms is as follows: The Pump Rooms Abbey Chambers Church St Avon Bath BA1 1LZ The Conference Dinner will take place at the Assembly Rooms from 7pm on Thursday 14July. 4 5 Programme v2_mono.indd 4 01/07/2016 16:23 The INRC and British Pharmacological Society would like to thank all sponsors and exhibitors for their generous support! ALKERMES Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system BRITISH JOURNAL OF PHARMACOLOGY (CNS) diseases. The company has a diversified commercial The British Journal of Pharmacology with an Impact product portfolio and a substantial clinical pipeline of Factor of 5.259 is the leading general pharmacology product candidates for chronic diseases that include journal. Broad-based in nature it publishes international schizophrenia, depression, addiction and multiple content across all aspects of experimental pharmacology sclerosis. Headquartered in Dublin, Ireland, Alkermes plc including high quality original research, authoritative has an R&D center in Waltham, Massachusetts; a research reviews, highly popular themed issues and virtual issues. and manufacturing facility in Athlone, Ireland; and a The must-read FREE supplement, the Concise Guide manufacturing facility in Wilmington, Ohio. For more to PHARMACOLOGY, provides concise overviews of the information, please visit Alkermes’ website at key properties of over 1,700 pharmacological targets. www.alkermes.com. Available online and via the iOS and Android apps, BJP is not to be missed. Book mark it today www.brjpharmacol.org BATH UNIVERSITY Bath University is one of the UK's leading universities both in terms of research and reputation for excellence in teaching, learning and graduate prospects. HELLOBIO In the REF 2014 research assessment 87 per cent of Bath High quality research tools at up to half the price of other University’s research was defined as ‘world-leading’ or suppliers! ‘internationally excellent’. From making aircraft more As experienced scientists, we aim to offer high quality fuel efficient, to identifying infectious diseases more research tools at prices so low that as many researchers as quickly, or cutting carbon emissions through innovative possible will be able to afford them. building solutions, research from Bath is making a difference around the world. Find out more: Our agonists, antagonists, inhibitors, activators, www.bath.ac.uk/research/ antibodies and fluorescent tools include: Well established as a nurturing environment for • Receptor ligands enterprising minds, Bath is ranked highly in all national • Ion channel modulators league tables. We were chosen as the UK’s top university • Enzyme modulators in the Times Higher Education Student Experience Survey • Signaling and stem cell tools 2015. Internationally, Bath was placed ‘first in Europe’ We’d love you to give us a try! according to the latest QS ‘Top 50 under 50’ ranking. • Up to half the price of other suppliers • Hello BioPromise quality guarantee • Fun science goodies 4 5 Programme v2_mono.indd 5 01/07/2016 16:23 HEPTARES NIDA Heptares Therapeutics is creating transformative NIDA is the lead federal agency supporting scientific medicines targeting G protein-coupled receptors (GPCRs), research on drug use and its consequences. Our mission a superfamily of receptors linked to many human is to advance science on the causes and consequences of ® diseases. Heptares’ proprietary StaR technology and drug use and addiction and to apply that knowledge to structure-based drug design (SBDD) capabilities enable improve individual and public health through: the generation of drugs (small molecules and biologics) for highly validated, yet historically undruggable or • Strategically supporting and conducting basic and challenging GPCRs. Using this approach, Heptares is clinical research on drug use (including nicotine), its building a pipeline of innovative new medicines with consequences, and the underlying neurobiological, potential to transform the treatment of Alzheimer’s behavioral, and social mechanisms involved disease, cancer, migraine, addiction, metabolic disease • Ensuring the effective translation, implementation, and other indications. Heptares has partnerships with and dissemination of scientific research findings to Allergan, AstraZeneca, Kymab, MorphoSys, Pfizer and improve the prevention and treatment of substance Teva. Heptares is a wholly owned subsidiary of Sosei Group use disorders and enhance public awareness of Corporation. addiction as a brain disorder LI-COR OREXIGEN LI-COR® Biosciences offers a complete discovery process Orexigen Therapeutics, Inc. is a biopharmaceutical including imaging platforms, analysis software and company focused on the treatment of obesity. Orexigen’s optimized IRDye® infrared dye reagents for protein and first medicine, Contrave® (naltrexone HCl and bupropion molecular imaging. Our complete solution for Western HCl extended release), was approved in the United blot imaging includes the Odyssey® and Odyssey Fc States in September 2014 and has become the most Infrared Imaging Systems, analysis software, and prescribed branded obesity medication since June unique IRDye Infrared Dye-based antibodies, and 2015.
Load more

Recommended publications
  • PDF File of All Submitted Abstracts
    APHAR 2012 Abstract Preview MEETING ABSTRACTS 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR) Joint Meeting with the Croatian, Serbian and Slovenian Pharmacological Societies Graz, Austria, 20–21 September 2012 A1 Acknowledgements: This work was supported in part by the Antidepressant-like effects of benzodiazepine site inverse Ministry of Education and Science, Republic of Serbia, grant no. agonists in the rat forced swim test 175076. Janko Samardžić and Dragan I Obradović Institute of Pharmacology, Clinical Pharmacology and Toxicology, A2 Medical Faculty, University of Belgrade, 11129 Belgrade, Serbia Methadone-drugs interactions: possible causes of methadone- E-mail: [email protected] related deaths Vesna Mijatović1, Isidora Samojlik1, Stojan Petković2 and Nikša Background: There are three kinds of allosteric modulators acting 2 Ajduković through the benzodiazepine (BZ) binding site of the GABA 1 A Department of Pharmacology, Toxicology and Clinical receptor: positive (agonist), neutral (antagonist), and negative Pharmacology, Faculty of Medicine, University of Novi Sad, 21000 (inverse agonist) modulators. Agonists and inverse agonists 2 Novi Sad, Serbia; Department of Forensic Medicine, Faculty of commonly exert bidirectional influences on observed behavioral Medicine, University of Novi Sad, 21000 Novi Sad, Serbia parameters. In the present study we have investigated the E-mail: [email protected] modulation of behavioral responses to environmental novelty in two unconditioned paradigms: spontaneous locomotor activity (SLA) and Background: Methadone is an effective analgesic and it is widely forced swim test (FST), elicited by DMCM (methyl-6,7-dimethoxy-4- used to suppress withdrawal symptoms from other opiates. Its ethyl-beta-carboline-3-carboxylate), a non-selective inverse agonist, consumption is usually associated with concomitant drug use in in the dose range that previously did not produce anxiogenic effects heroin addicts, and this combination is a possible risk factor for and convulsions.
    [Show full text]
  • In Vitro Pharmacological Characterization of a Novel Unbiased NOP Receptor-Selective Nonpeptide Agonist AT-403 Federica Ferrari1, Davide Malfacini1, Blair V
    ORIGINAL ARTICLE In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403 Federica Ferrari1, Davide Malfacini1, Blair V. Journigan2, Mark F. Bird3, Claudio Trapella4, Remo Guerrini4, David G. Lambert3, Girolamo Calo’1 & Nurulain T. Zaveri2 1Section of Pharmacology, Department of Medical Sciences and National Institute of Neurosciences University of Ferrara, Ferrara, Italy 2Astraea Therapeutics, LLC. 320 Logue Avenue, Mountain View, California 3Division of Anaesthesia, Department of Cardiovascular Sciences, University of Leicester, Critical Care and Pain Management, Leicester Royal Infirmary, Leicester, United Kingdom 4Department of Chemical and Pharmaceutical Sciences and LTTA, University of Ferrara, Ferrara, Italy Keywords Abstract BRET arrestin assay, functional selectivity, GPCR signaling bias, ligand bias, nonpeptide Nociceptin/orphanin FQ (N/OFQ) regulates several biological functions via NOP agonists, NOP receptor selective activation of the N/OFQ receptor (NOP), a member of the opioid receptor family. We recently identified a new high affinity and highly selective Correspondence NOP agonist AT-403. In this study, we characterized the functional profile of Nurulain T. Zaveri, Astraea Therapeutics, 320 AT-403 and compared it to other known nonpeptide NOP agonists Ro 65- Logue Avenue, Suite 142, Mountain View, 6570, Ro 2q, SCH-221510, MCOPPB, AT-202 and SCH-486757, using the fol- CA 94043. Tel: 650 254 0786; lowing assays: GTPc[35S] stimulated binding, calcium mobilization assay in Fax: 1 844 457 7470; E-mail: [email protected] cells-expressing human NOP or classical opioid receptors and chimeric G pro- teins, bioluminescence resonance energy transfer (BRET) based assay for study- Funding Information ing NOP receptor interaction with G protein and arrestin, and the electrically This work was supported by funds from the stimulated mouse vas deferens bioassay.
    [Show full text]
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn
    Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn By © 2018 Solomon Aguta Gisemba Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Dr. Michael Rafferty Dr. Teruna Siahaan Dr. Thomas Tolbert Date Defended: 18 April 2018 The dissertation committee for Solomon Aguta Gisemba certifies that this is the approved version of the following dissertation: Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Date Approved: 10 June 2018 ii Abstract Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 1,2,3 4 8 depression. Arodyn (Ac[Phe ,Arg ,D-Ala ]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the bioactive conformation to give potent and selective analogs. Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of isomerization suppressants were applied to the synthesis of cyclic arodyn analogs.
    [Show full text]
  • Prescription Drug Management
    Check out our new site: www.acllaboratories.com Prescription Drug Management Non Adherence, Drug Misuse, Increased Healthcare Costs Reports from the Centers for DiseasePrescription Control and Prevention (CDC) say Drug deaths from Managementmedication overdose have risen for 11 straight years. In 2008 more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription Nondrugs. Adherence,1 Drug Misuse, Increased Healthcare Costs The CDC analysis found that nearly 40,000 drug overdose deaths were reported in 2010. Prescribed medication accounted for almost 60 percent of the fatalities—far more than deaths from illegal street drugs. Abuse of painkillers like ReportsOxyContin from and the VicodinCenters forwere Disease linked Control to the and majority Prevention of the (CDC) deaths, say deaths from according to the report.1 medication overdose have risen for 11 straight years. In 2008 more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription drugs. 1 A health economics study analyzed managed care claims of more than 18 million patients, finding that patients undergoing opioid therapyThe CDCfor chronic analysis pain found who that may nearly not 40,000 be following drug overdose their prescription deaths were regimenreported in 2010. Prescribed medication accounted for almost 60 percent of the fatalities—far more than deaths have significantly higher overall healthcare costs. from illegal street drugs. Abuse of painkillers like OxyContin and Vicodin were linked to the majority of the deaths, according to the report.1 ACL offers drug management testing to provide information that can aid clinicians in therapy and monitoring to help improve patientA health outcomes.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • LC-MS for Pain Management Support
    LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline .Overview of drug testing, as a component of the therapeutic plan, in the management of chronic pain .A mini-SWOT analysis for application of LC- MS to pain management drug testing .Considerations for optimizing utility of LC-MS results Drug testing in pain management . Baseline testing, before initiating opioid therapy . Routine testing . Periodic, based on patient risk assessment . To evaluate changes . Therapeutic plan (drugs, formulations, dosing) . Clinical response (poor pain control, toxicity) . Clinical events (disease, surgery, pregnancy) . Patient behavior Objectives of drug testing Non- Detect and encourage Adherence appropriate drug use Detect and discourage Adherence inappropriate drug use Traditional approach . Immunoassay-based screen Screen . Confirm screen positive results with mass spectrometric method (GC-MS, LC-MS) Not appropriate for pain management Confirm + . Reflex testing leads to unnecessary expenses if the results are consistent with expectations, or if results are not used to make patient care decisions Confirm + . Confirmation of negative results may be more important than confirmation of positive results . Immunoassay-based screens may not be available Confirm + for specimens and drugs of interest Drugs monitored for pain management represent ~25% of “Top 200” prescriptions filled, 2011 .Analgesics .Anxiolytics, muscle . Hydrocodone (#1, 2, 14, 139) relaxants . Oxycodone (#45, 48, 121, 129, 196)
    [Show full text]
  • 169 2016 Interim Meeting Science and Public Health - 1
    169 2016 Interim Meeting Science and Public Health - 1 REPORTS OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH The following reports, 1–4, were presented by S. Bobby Mukkamala, MD, Chair: 1. URINE DRUG TESTING Reference committee hearing: see report of Reference Committee K. HOUSE ACTION: RECOMMENDATIONS ADOPTED AS FOLLOWS REMAINDER OF REPORT FILED See Policies H-95.985 and D-120.936 INTRODUCTION Over the past two decades, the rate of opioid prescribing, especially for patients with chronic non-cancer pain, has increased dramatically. It is estimated that between 9.6 and 11.5 million Americans are currently being prescribed long-term opioid therapy.1 The overall increase in prescribing has been associated with a parallel increase in unintentional overdoses and deaths from prescription opioids.2 In 2014, a total of 47,055 drug overdose deaths occurred in the United States; 61% of these involved some type of opioid, including heroin. Overdose deaths from heroin have quadrupled in recent years, and the majority of past year users of heroin report they used opioids in a nonmedical fashion prior to heroin initiation; hence, the availability of pharmaceutical opioids is relevant to the national heroin use and overdose death epidemics. In the most recent available report, benzodiazepines were involved in 31% of the opioid-related overdoses.3 Despite clinical recommendations to the contrary, the rate of opioid and benzodiazepine co-prescribing also continues to rise.3-5 Identifying patients at risk for drug misuse is a challenge. There is no definitive way for physicians to predict which of their patients will develop misuse problems with controlled substances.
    [Show full text]
  • Biased Signaling by Endogenous Opioid Peptides
    Biased signaling by endogenous opioid peptides Ivone Gomesa, Salvador Sierrab,1, Lindsay Lueptowc,1, Achla Guptaa,1, Shawn Goutyd, Elyssa B. Margolise, Brian M. Coxd, and Lakshmi A. Devia,2 aDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Physiology & Biophysics, Virginia Commonwealth University, Richmond, VA 23298; cSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095; dDepartment of Pharmacology & Molecular Therapeutics, Uniformed Services University, Bethesda MD 20814; and eDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94143 Edited by Susan G. Amara, National Institutes of Health, Bethesda, MD, and approved April 14, 2020 (received for review January 20, 2020) Opioids, such as morphine and fentanyl, are widely used for the possibility that endogenous opioid peptides could vary in this treatment of severe pain; however, prolonged treatment with manner as well (13). these drugs leads to the development of tolerance and can lead to For opioid receptors, studies showed that mice lacking opioid use disorder. The “Opioid Epidemic” has generated a drive β-arrestin2 exhibited enhanced and prolonged morphine-mediated for a deeper understanding of the fundamental signaling mecha- antinociception, and a reduction in side-effects, such as devel- nisms of opioid receptors. It is generally thought that the three opment of tolerance and acute constipation (15, 16). This led to types of opioid receptors (μ, δ, κ) are activated by endogenous studies examining whether μOR agonists exhibit biased signaling peptides derived from three different precursors: Proopiomelano- (17–20), and to the identification of agonists that preferentially cortin, proenkephalin, and prodynorphin.
    [Show full text]
  • Structure of the Human Κ-Opioid Receptor in Complex with Jdtic
    ARTICLE doi:10.1038/nature10939 Structure of the human k-opioid receptor in complex with JDTic Huixian Wu1, Daniel Wacker1, Mauro Mileni1, Vsevolod Katritch1, Gye Won Han1, Eyal Vardy2, Wei Liu1, Aaron A. Thompson1, Xi-Ping Huang2, F. Ivy Carroll3, S. Wayne Mascarella3, Richard B. Westkaemper4, Philip D. Mosier4, Bryan L. Roth2, Vadim Cherezov1 & Raymond C. Stevens1 Opioid receptors mediate the actions of endogenous and exogenous opioids on many physiological processes, including the regulation of pain, respiratory drive, mood, and—in the case of k-opioid receptor (k-OR)—dysphoria and psychotomimesis. Here we report the crystal structure of the human k-OR in complex with the selective antagonist JDTic, arranged in parallel dimers, at 2.9 A˚ resolution. The structure reveals important features of the ligand-binding pocket that contribute to the high affinity and subtype selectivity of JDTic for the human k-OR. Modelling of other important k-OR-selective ligands, including the morphinan-derived antagonists norbinaltorphimine and 59-guanidinonaltrindole, and the diterpene agonist salvinorin A analogue RB-64, reveals both common and distinct features for binding these diverse chemotypes. Analysis of site-directed mutagenesis and ligand structure–activity relationships confirms the interactions observed in the crystal structure, thereby providing a molecular explanation for k-OR subtype selectivity, and essential insights for the design of compounds with new pharmacological properties targeting the human k-OR. The four opioid receptors, m, d, k and the nociceptin/orphanin FQ antidepressants, anxiolytics and anti-addiction medications14, whereas peptide receptor, belong to the class A (rhodopsin-like) c subfamily of a widely abused, naturally occurring hallucinogen—salvinorin A G-protein-coupled receptors (GPCRs)1 with a common seven- (SalA)—was also found to be a highly selective k-OR agonist15.
    [Show full text]
  • The Effects of Morphine, Naloxone, and Оє Opioid Manipulation On
    Neuroscience 287 (2015) 32–42 THE EFFECTS OF MORPHINE, NALOXONE, AND j OPIOID MANIPULATION ON ENDOCRINE FUNCTIONING AND SOCIAL BEHAVIOR IN MONOGAMOUS TITI MONKEYS (CALLICEBUS CUPREUS) B. J. RAGEN, a,b* N. MANINGER, b S. P. MENDOZA b AND Key words: titi monkey, mu opioid, pair-bonding, cortisol, K. L. BALES a,b monogamy, kappa opioid. a Psychology Department, University of California-Davis, One Shields Avenue, Davis, CA 95616, USA b California National Primate Research Center, One Shields INTRODUCTION Avenue, Davis, CA 95616, USA Socially monogamous species form long-term associations between two adults. In some species, Abstract—The l opioid receptor (MOR) and j opioid recep- these relationships have been shown to be classic tor (KOR) have been implicated in pair-bond formation and attachment bonds (Hazan and Shaver, 1987) and result maintenance in socially monogamous species. Utilizing in pair-mates spending considerable time in physical con- monogamous titi monkeys (Callicebus cupreus), the present tact with one another, providing social buffering, and study examined the potential role opioids play in modulat- exhibiting substantial behavioral and physiological agita- ing the response to separation, a potent challenge to the tion upon involuntary separation (Mason and Mendoza, pair-bond. In Experiment 1, paired male titi monkeys were separated from their pair-mate for 30-min and then received 1998). Due to the rarity of monogamy in mammals saline, naloxone (1.0 mg/kg), morphine (0.25 mg/kg), or the (Kleiman, 1977) there is a paucity of data on the neurobio- KOR agonist, U50,488 (0.01, 0.03, or 0.1 mg/kg) in a coun- logical underpinnings of adult attachment.
    [Show full text]
  • Phosphoproteomics Illuminates Opioid Actions Tao Che and Bryan L
    Phosphoproteomics Illuminates Opioid Actions Tao Che and Bryan L. Roth* Department of Pharmacology, University of North Carolina School of Medical, Chapel Hill, North Carolina 27514, United States ABSTRACT: Opioids are widely used analgesic medications with a high potential for tolerance and dependence and represent a frequent cause of death due to overdose. Opioids mediate their actions via a family of opioid G protein coupled receptors. Elucidating the biochemical mechanism(s) responsible for both the therapeutic and deleterious side effects of opioids could provide a biochemical roadmap for selectively targeting therapeutic signaling pathways. Here we provide a perspective on emerging findings, which illuminate these signaling pathways via unbiased and quantitative phosphoproteomic analysis. What emerged from these studies is the discovery that certain deleterious actions mediated by the κ opioid receptors appear due to specific activation of mTOR pathways. The findings imply that designing drugs, which bypass mTOR signaling, could yield safer and more effective analgesics. pioid drugs like morphine and oxycodone are powerful with the use of dynorphin- and KOR-knockout mice, they O painkillers that produce analgesia by activation of opioid identified the phosphorylation sites uniquely related to KOR G-protein coupled receptors (GPCRs). Although opioids are activation. The authors determined that the dynamic changes quite useful for alleviating pain, they can also elicit an array of in KOR phosphorylation displayed spatio-temporal control. harmful side effects, such as aversion, hallucinations, addiction, Further analysis of KOR-mediated phosphorylation identified and death by respiratory depression. Thus, a new class of those patterns relevant to specific neuronal circuits, in nonopioid analgesics could go a long way toward alleviating particular, dopamine-, glutamate-, and γ-aminobutyric acid the prevailing opioid crisis.
    [Show full text]